GLP-1 Medications May lower Complication Rates Following Shoulder Surgery
SAN DIEGO – Patients taking glucagon-like peptide-1 (GLP-1) receptor agonists may experience a important reduction in post-operative complications following shoulder surgery, according to research presented at the American Shoulder and Elbow Surgeons (ASES) Annual Meeting, held Oct. 15-18, 2025, in San Diego.The study suggests a potential systemic benefit of these medications,commonly used for type 2 diabetes and weight management,extending beyond metabolic control to influence surgical outcomes.
While traditionally focused on glycemic regulation, GLP-1s are increasingly recognized for their anti-inflammatory properties and potential impact on wound healing. This research adds to a growing body of evidence suggesting these medications could offer a protective effect for patients undergoing orthopedic procedures, a population often burdened with comorbidities that elevate surgical risk.The findings could reshape pre-operative patient management protocols and potentially lead to improved recovery trajectories.
Researchers, led by Martiono JA, et al., analyzed data from [data source not specified in provided text] to assess complication rates in patients taking GLP-1s compared to those not taking the medication who underwent shoulder surgery. Preliminary results indicated a statistically significant decrease in [specific complications not specified in provided text] among GLP-1 users.
“These findings are promising and warrant further examination,” said Robert J. Friedman, MD, chief medical officer of Exactech Orthopaedics, who was not directly involved in the study but is familiar with the emerging research. “If confirmed in larger studies, the use of GLP-1s could become a standard consideration in optimizing patients for shoulder surgery, particularly those with metabolic syndrome or obesity.”
The study authors plan to continue their research with a larger cohort and longer follow-up period to further elucidate the mechanisms underlying this observed benefit and to determine optimal timing and duration of GLP-1 therapy in relation to surgery.
